NCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
Clinical Trials
40 trialsNCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT06118047 2023-11-07
COSTIC
Sun Yat-sen University
Phase 2 Unknown
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05684211 2023-02-01
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
Phase 2 Unknown
NCT05497336 2022-09-30
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT05103020 2021-11-02
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Yonsei University
Phase 2 Unknown
NCT04241731 2021-08-30
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04466254 2021-08-23
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT03727763 2021-08-19
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02942706 2021-04-30
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT04833036 2021-04-06
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
Fudan University
Phase 2 Unknown
NCT04668976 2020-12-21
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
Phase 2 Unknown
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04509635 2020-08-12
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Fudan University
Phase 3 Unknown
NCT03491709 2019-10-31
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Dragonboat Biopharmaceutical Company Limited
Phase 1 Unknown
NCT01802645 2019-09-11
CELIM2
Technische Universität Dresden
Phase 2 Unknown
NCT03356158 2018-09-17
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1 Unknown
NCT02296203 2018-02-15
CRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Unknown
NCT03401957 2018-01-17
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
National Health Research Institutes, Taiwan
Unknown
NCT02717923 2017-10-23
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
Huazhong University of Science and Technology
Phase 2 Unknown
NCT02978313 2016-11-30
Cetuximab Monotherapy Maintenance Treatment in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT02515734 2015-08-05
DEEPER
Japan Clinical Cancer Research Organization
Phase 2 Unknown
NCT00433927 2014-03-14
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Phase 3 Unknown
NCT01315990 2013-12-18
DERMATUX
Johannes Gutenberg University Mainz
Phase 4 Unknown
NCT00852228 2013-12-12
OPTILIV
Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Phase 2 Unknown
NCT01190462 2013-08-12
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00482222 2013-01-23
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
Phase 3 Unknown
NCT01564810 2012-10-24
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
Fudan University
Phase 4 Unknown
NCT00438737 2011-09-02
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01322178 2011-08-12
CLIME
Fudan University
Phase 2 Unknown
NCT00392470 2011-05-25
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00784667 2010-11-30
Dux
Austin Health
Phase 2 Unknown
NCT01166035 2010-07-20
TEXO
Medical University Innsbruck
Phase 1/2 Unknown
NCT00383695 2010-01-13
EXPERT-C
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00215722 2007-04-06
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
Grupo de Investigacao do Cancro Digestivo
Phase 2 Unknown